Supreme Court Blocks Restrictions, Preserves Nationwide Access to Abortion Pill Mifepristone

The U.S. Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a lower court ruling that threatened to upend one of the primary methods of abortion access nationwide.

The order, signed by Justice Samuel Alito, temporarily allows women seeking abortions to obtain the pill at pharmacies or through the mail without requiring an in-person visit to a doctor.

This decision marks a significant development in the ongoing legal battle over abortion access following the overturning of Roe v. Wade in June 2022. The Supreme Court’s intervention prevents immediate restrictions on mifepristone distribution that could have taken effect as early as April 7, 2023.

The case originated from a challenge by anti-abortion groups and doctors who argued that the FDA’s approval of mifepristone in 2000 was improper. A federal judge in Texas initially ruled to suspend the drug’s approval, but the Supreme Court’s temporary order puts that ruling on hold while appeals proceed.

Mifepristone, used in combination with misoprostol, is the most common method for medication abortions in the United States, accounting for over half of all abortions performed in the country. The pill regimen is approved for use up to 10 weeks of pregnancy.

Justice Alito’s order applies nationwide and remains in effect while the Supreme Court reviews the case. The decision does not address the broader legality of abortion but focuses specifically on the distribution of mifepristone.

Legal experts note that this order is a temporary measure and does not represent a final ruling on the merits of the case. The Supreme Court is expected to hear arguments on the appeal in the coming months.